Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Profund Advisors LLC

Profund Advisors LLC boosted its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 208.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,783 shares of the specialty pharmaceutical company’s stock after purchasing an additional 5,256 shares during the quarter. Profund Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $1,802,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of JAZZ. Bank of New York Mellon Corp increased its holdings in Jazz Pharmaceuticals by 44.5% during the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after buying an additional 517,514 shares during the period. Bank of America Corp DE lifted its holdings in Jazz Pharmaceuticals by 10.9% during the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after buying an additional 99,656 shares during the period. Systematic Financial Management LP lifted its holdings in Jazz Pharmaceuticals by 2.6% during the first quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company’s stock worth $76,965,000 after buying an additional 10,237 shares during the period. Quantinno Capital Management LP boosted its position in Jazz Pharmaceuticals by 9.7% during the 1st quarter. Quantinno Capital Management LP now owns 191,286 shares of the specialty pharmaceutical company’s stock valued at $36,163,000 after acquiring an additional 16,928 shares in the last quarter. Finally, Tri Locum Partners LP bought a new stake in Jazz Pharmaceuticals during the 1st quarter valued at $29,995,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $214.44 on Tuesday. The firm’s fifty day simple moving average is $231.16 and its two-hundred day simple moving average is $216.50. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals PLC has a 12-month low of $128.80 and a 12-month high of $266.38. The firm has a market capitalization of $13.92 billion, a P/E ratio of 8.88, a P/E/G ratio of 0.41 and a beta of 0.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.05) by $0.17. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the prior year, the firm posted $8.13 earnings per share. The business’s quarterly revenue was up 10.4% on a year-over-year basis. Analysts forecast that Jazz Pharmaceuticals PLC will post 10.87 EPS for the current fiscal year.

Jazz Pharmaceuticals News Roundup

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz reported third-quarter revenue of approximately $1.24 billion, up 10.4% year over year and ahead of the roughly $1.21 billion analyst estimate. The company also raised its full-year 2026 total revenue guidance, signaling confidence in commercial execution. Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Xywav revenue increased 12% year over year, with 425 net patient additions during the quarter. Jazz also launched Ziihera in first-line HER2-positive metastatic or unresectable gastric and esophageal cancer, expanding its commercial opportunity. Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
• Positive Sentiment: The completed Actio acquisition adds the ABS-1230 candidate to Jazz’s rare-epilepsy pipeline. Separately, the company plans to present additional neuro-oncology research and Phase 3 ACTION trial progress at the Society for Neuro-Oncology meeting, potentially providing future clinical catalysts. Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026
• Neutral Sentiment: Management characterized the quarter as evidence of sustained execution and discussed the results during the earnings call. Investors will likely focus on the details behind the higher revenue outlook, product trends and pipeline priorities. Jazz Pharmaceuticals Q3 2026 Earnings Call Transcript
• Negative Sentiment: Jazz posted a quarterly loss of $3.88 per share, although it was better than the consensus loss estimate of approximately $4.05-$4.09. The result compares with earnings of $8.13 per share a year earlier, creating a significant year-over-year deterioration that may be weighing on the stock. Jazz Pharmaceuticals Reports Q3 Loss, Tops Revenue Estimates

Analyst Ratings Changes

A number of research analysts have recently issued reports on JAZZ shares. Royal Bank Of Canada cut their price target on Jazz Pharmaceuticals from $299.00 to $296.00 and set an “outperform” rating on the stock in a report on Thursday, October 8th. Needham & Company LLC upped their price objective on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, August 26th. Deutsche Bank Aktiengesellschaft upped their price objective on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research note on Wednesday, August 26th. Weiss Ratings downgraded Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, October 28th. Finally, TD Cowen lifted their target price on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $292.05.

Insiders Place Their Bets

In related news, EVP Neena Patil sold 1,200 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $240.94, for a total transaction of $289,128.00. Following the transaction, the executive vice president directly owned 47,671 shares of the company’s stock, valued at $11,485,850.74. This represents a 2.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the sale, the executive vice president owned 65,686 shares of the company’s stock, valued at approximately $16,401,794.20. This trade represents a 53.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 94,121 shares of company stock valued at $23,337,922 in the last 90 days. Corporate insiders own 4.10% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.